Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Mirum Pharmaceuticals ( (MIRM) ).
On May 4, 2026, Mirum Pharmaceuticals reported that its VISTAS Phase 2b trial of volixibat in 158 patients with primary sclerosing cholangitis met its primary endpoint, showing a 2.72-point improvement in pruritus and a placebo-adjusted 1.64-point benefit on the Adult ItchRO scale in the moderate-to-severe itch cohort, with statistically significant effects emerging within two weeks and extending to patients with mild itch. The safety profile was consistent with expectations for IBAT inhibition, with mainly gastrointestinal adverse events and more frequent liver parameter elevations in the active arm, and the company is now preparing for a pre-New Drug Application meeting with the U.S. Food and Drug Administration in summer 2026, an NDA submission in the second half of 2026, and anticipates topline Phase 2b data for volixibat in primary biliary cholangitis in the first quarter of 2027, underscoring its bid to deliver the first approved therapy for cholestatic pruritus in PSC and potentially expanding its reach in cholestatic liver disease.
The most recent analyst rating on (MIRM) stock is a Buy with a $126.00 price target. To see the full list of analyst forecasts on Mirum Pharmaceuticals stock, see the MIRM Stock Forecast page.
Spark’s Take on MIRM Stock
According to Spark, TipRanks’ AI Analyst, MIRM is a Neutral.
The score is driven primarily by improving fundamentals—strong revenue growth, high gross margins, and newly positive operating/free cash flow—tempered by continued losses and meaningful leverage. Earnings-call takeaways are supportive (solid 2026 sales guidance and multiple catalysts) but include a sizable 2026 R&D spend increase and growth deceleration. Technically the stock is soft in the near term, and valuation is constrained by negative earnings and no dividend.
To see Spark’s full report on MIRM stock, click here.
More about Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for liver diseases, with a focus on cholestatic conditions such as primary sclerosing cholangitis and primary biliary cholangitis. Its pipeline includes volixibat, an oral ileal bile acid transporter inhibitor aimed at addressing cholestatic pruritus, a significant unmet need in these patient populations.
Average Trading Volume: 793,684
Technical Sentiment Signal: Buy
Current Market Cap: $5.82B
For an in-depth examination of MIRM stock, go to TipRanks’ Overview page.